Obesity has become an escalating global health issue, and the therapeutic efficacy of conventional anti-obesity medications is frequently limited by adverse side effects.Flavonoids, a diverse class of polyphenolic compounds abundant in fruits, vegetables, and other plant-derived foods, have emerged as promising adjunctive agents for obesity management.Evidence from laboratory and animal studies highlights their multifaceted anti-obesity mechanisms, including regulation of lipid metabolism via AMPactivated protein kinase and PPAR activation, promotion of white adipose tissue browning, modulation of gut microbiota, and potent anti-inflammatory, and antioxidant activities.In addition, flavonoids improve insulin sensitivity and glucose metabolism, thereby disrupting the cycle of obesity and insulin resistance.Dietary patterns rich in flavonoids-such as the Mediterranean, Nordic, Asian, and African heritage diets-are consistently associated with reduced obesity risk and more favorable metabolic profiles.Despite these benefits, clinical application is hindered by low bioavailability and rapid systemic clearance.Overcoming these obstacles will require long-term human trials and technological advances, such as nanoencapsulation, to enhance delivery and efficacy.In summary, flavonoids represent a compelling candidate for safe, natural strategies in obesity management, although further research is essential to optimize their clinical use and confirm their effectiveness in humans.